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Abstract
Introduction: The prevalence of antibodies to RNA polymerase III (anti-RNAP) differs among systemic sclerosis
(SSc) cohorts worldwide. Previously reported associations of anti-RNAP include diffuse cutaneous disease, tendon
friction rubs and renal crisis, with recent reports suggesting a close temporal association between malignancy and
SSc disease onset among patients with anti-RNAP.
Methods: Patients with SSc were tested for the presence of anti-RNAP at recruitment into the Australian
Scleroderma Cohort Study. We used univariate and multivariable methods to identify and quantify clinical and
laboratory correlates of anti-RNAP in SSc. Diagnostic testing procedures were used to determine the usefulness of
these antibodies in estimating the likelihood of clinically important outcomes.
Results: There were 451 patients with mean ± standard deviation age and disease duration at recruitment of
58.1 ± 12.4 and 11.6 ± 10.0 years, respectively; 151 (33.5%) patients were recruited within 5 years of diagnosis
of SSc. Overall, 69 (15.3%) patients had anti-RNAP. Univariate associations of anti-RNAP were diffuse disease
(75.4% vs. 20.9%, P < 0.0001), joint contractures (73.9% vs. 30.1%, P < 0.0001), greater highest-recorded
modified Rodnan skin score (20.6 ± 12.4 vs. 10.1 ± 7.9, P < 0.0001), synovitis (31.9% vs. 19.9%, P = 0.03),
myositis (2.9% vs. 0.5%, P = 0.05), systemic hypertension (59.4% vs. 39.7%, P = 0.002), renal crisis (24.6% vs.
1.8%, P < 0.0001) and malignancy diagnosed within 5 years of onset of SSc skin disease (13.3% vs. 3.9%, P =
0.01). In multiple regression analysis, after adjustment for other covariates, anti-RNAP were independently
associated with renal crisis (odds ratio (OR) 3.8, 95% confidence interval (CI) 1.2 to 11.5, P = 0.02; positive
predictive value (PPV) 24.6%, negative predictive value (NPV) 98.2%), diffuse disease (OR 6.4, 95% CI 2.9 to 13.8,
P < 0.0001; PPV 75.4%, NPV 20.9%), joint contractures (OR 2.5, 95% CI 1.2 to 5.3, P = 0.02; PPV 73.9%, NPV
69.9%) and malignancy diagnosed within 5 years of onset of SSc skin disease (OR 4.2, 95% CI 1.3 to 13.4, P =
0.01; PPV 13.3%, NPV 96.1%).
Conclusions: Anti-RNAP status is a clinically useful prognostic marker in SSc and enables clinicians to identify
patients at high risk of developing renal crisis, synovitis, myositis and joint contractures. Patients with anti-RNAP
also have an increased risk of malignancy within a 5-year timeframe before or after onset of SSc skin changes.
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Systemic sclerosis (SSc) is a multisystem autoimmune
disease characterized by vasculopathy and fibrosis [1].
The various manifestations of SSc in affected individuals
evolve over time and range from digital ischemia and
ulcers to potentially life-threatening renal crisis, intersti-
tial lung disease (ILD) and pulmonary arterial hyperten-
sion (PAH). This heterogeneity of clinical manifestations
in SSc has led to efforts to find markers that enable
identification of patients most at risk of involvement of
particular organ systems, who would benefit from more
frequent and organ-specific monitoring.
Antibodies to RNA polymerase III (anti-RNAP),
detected by immunoprecipitation, were first shown to
have specificity for the diagnosis of SSc in the early 1990s
[2]. More recently, through the availability of commercial
ELISAs, various clinical correlates of anti-RNAP in SSc
have been described [3]. Whilst these antibodies are cur-
rently thought not to play a pathogenic role, they have
prognostic significance. Anti-RNAP appear early in the
course of SSc, and, although there is considerable intra-
patient and inter-patient variability in antibody titers over
time, actual levels do not correlate with disease outcome
[4]. A baseline measurement is therefore often sufficient.
The reported frequency of anti-RNAP in various SSc
cohorts ranges from 4 to 9.4% in French SSc patients
[5-7], to 12% in English SSc patients [8], 6% in Japanese
SSc patients [9], 19.4% in Canadian SSc patients [10]
and 25% in American SSc patients [7] Racial and genetic
variations are hypothesized to account for these
differences.
Previously reported associations of anti-RNAP include
diffuse cutaneous disease, higher maximum skin thick-
ness score, tendon friction rubs and renal crisis
[2,6,8,10-13]. Two recent studies have reported a close
temporal association between the onset of SSc and diag-
nosis of cancer among SSc patients with anti-RNAP
[14,15]. This association, however, is yet to be confirmed
and quantified in large prospective studies.
In the present study, our objective was to determine
the prevalence of anti-RNAP in a large Australian
cohort of patients with SSc. We sought to confirm and
quantify previously described associations and to define
novel clinical and laboratory correlates of these antibo-
dies. We applied diagnostic testing procedures in order
to determine the usefulness of these antibodies in esti-
mating the likelihood of clinically important outcomes,
including malignancy.
Materials and methods
Patients
Consecutive patients recruited into the Australian Scler-
oderma Cohort Study - a prospective cohort study of
risk factors for clinically important outcomes in SSc -
were included in the study. These patients fulfilled
either the American College of Rheumatology criteria
for classification of SSc or the Medsger criteria for lim-
ited SSc [16,17]. Patients with mixed connective tissue
disease were excluded. Participants were recruited from
seven centers specializing in the care of patients with
SSc: St. Vincent’s Hospital and Monash Medical Centre,
Melbourne; Sunshine Coast Rheumatology, Queensland;
Royal Adelaide Hospital, South Australia; St George
Hospital, Sydney; Royal Perth Hospital, Western Austra-
lia; and Prince Charles Hospital, Brisbane. After obtain-
ing informed consent, demographic and disease-related
data (including clinical and laboratory variables) were
collected, according to a standardized protocol, at
recruitment and at each subsequent annual visit. The
study was approved by the human research ethics com-
mittees of each of the participating centers.
Measurement of antibodies to RNA polymerase III
Anti-RNAP were measured in serum samples drawn
from all patients at recruitment, from 2008 to 2009,
using one of two commercial ELISA kits available in
Australia: Quanta Lite RNA Pol III (Integrated Sciences,
Sydney, NSW, Australia) and MBL Anti-RNA Pol III
(Abacus ALS, Brisbane, QLD, Australia). Manufacturer-
specified cut-off points were used to define anti-RNAP
as present or absent. Both ELISA assays use a purified
recombinant immunodominant fragment of RNA poly-
merase III. Both assays have been validated against an
immunoprecipitation assay, with which they have 96%
positive agreement and 98% negative agreement. The
two ELISA assays are deemed equivalent.
Demographic, clinical and laboratory variables
Demographic data collected at recruitment included sex,
race, age at disease onset and at recruitment into the
study. Race was categorized as Caucasian, Asian, Abori-
ginal or Torres Strait Islander. Disease onset was
defined as the date of onset of the first manifestation of
SSc, other than Raynaud’s phenomenon.
For analysis, data were censored on 31 December
2010. Disease duration at recruitment and also at the
time of analysis of data was recorded. Duration of fol-
low-up was defined as the length of time from recruit-
ment to the date at which the data were censored for
analysis.
Disease-related data included SSc subtype (limited or
diffuse), defined by American College of Rheumatology
or Medsger criteria [16,17], and the highest modified
Rodnan skin score (mRSS) recorded at the annual fol-
low-up visit [18]. Disease manifestations were defined in
each patient as present ever from disease onset to most
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(with characteristic color changes), digital ulcers and
gangrene. Tendon friction rubs, joint contractures and
synovitis were diagnosed clinically by the treating physi-
cian, at the time of assessment. Myositis was defined as
t h ep r e s e n c eo fm u s c l ew e a k n e s sa n d / o rm u s c l ep a i n
with an elevated serum creatinine kinase, or the pre-
sence of inflammatory muscle disease on a muscle
biopsy. Creatinine kinase was measured and recorded at
each annual visit and the highest level recorded was
used for analysis.
Renal crisis was defined as an abrupt onset of severe
hypertension (systolic blood pressure (BP) ≥ 180 mmHg
and/or diastolic BP ≥ 100 mmHg) without an alternate
etiology, with or without microangiopathic anemia or
decline in renal function. Serum creatinine, estimated
glomerular filtration rate, need for dialysis or renal
transplantation, and presence of systemic hypertension
(systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg)
were also recorded at each annual visit. Gastrointestinal
involvement was defined as one or more of symptomatic
or endoscopically proven esophageal reflux, esophageal
dysmotility or esophageal stricture, gastric antral vascu-
lar ectasia, or symptoms of fecal incontinence or small
bowel involvement such as pseudo-obstruction with a
positive response to antibiotics, or radiographically pro-
ven small bowel involvement either by barium studies
or prolonged nuclear transit time. PAH was defined on
right heart catheterization as a mean pulmonary artery
pressure ≥ 25 mmHg with a pulmonary capillary wedge
pressure ≤ 15 mmHg. ILD was defined as the presence
of pulmonary fibrosis on high-resolution computerized
tomography scanning of the lungs. The need for home
oxygen, either for severe PAH or severe ILD, was also
recorded. SSc cardiac involvement was defined as the
presence of either left ventricular systolic or diastolic
dysfunction where no other cause was identified, or a
conduction disturbance unexplained by other mechan-
isms, or a characteristic histological picture on endo-
myocardial biopsy.
The type and date of diagnosis of malignancies were
recorded. We included malignancies that pre-dated or
post-dated the diagnosis of SSc. Where applicable, the
diagnosis of malignancy required histological confirma-
tion. Malignancies were categorized as solid organ,
hematopoietic or skin (nonmelanoma or melanoma).
The ‘other’ category comprised neoplastic variants such
as amyloidosis and pre-neoplastic conditions. Smoking
was defined as having ever smoked.
SSc treatment was defined in each patient as present
ever from disease onset to most recent visit, and was
categorized as corticosteroids (including prednisolone
but excluding intra-articular injections), antimalarials
(hydroxychloroquine), immunosuppressives
(methotrexate, azathioprine, mycophenolate mofetil,
cyclosporine and cyclophosphamide) and biological
therapies (rituximab and TNF antagonists).
At recruitment, in addition to testing for anti-RNAP,
all patients also underwent autoantibody profiling using
commercially available assays for: antinuclear antibody;
antibodies to extractable nuclear antigens (Orgentec
ELISA, Mainz, Germany) including antibodies to Scl70,
J o - 1 ,R N P ,R o6 0 ,L a ,S ma n dP M - S c l ;a n t i b o d i e st o
double-stranded DNA (Amerlex radioimmunoassay; Tri-
nity Biotech, Bray, Ireland); anti-neutrophil cytoplasmic
antibodies (Orgentec ELISA) including proteinase-3 or
myeloperoxidase specificity; rheumatoid factor; anti-
phospholipid antibodies including anti-cardiolipin anti-
bodies (Vital Diagnostics, Bella Vista, NSW, Australia);
and anti-b2 glycoprotein antibodies (Orgentec ELISA).
Study design
In a cross-sectional analysis of longitudinally acquired
data, demographic, clinical and laboratory correlates (as
defined above) of anti-RNAP were determined, using
univariate and multiple regression analyses. Among
patients ever diagnosed with malignancy, the type and
date of diagnosis of cancer relative to the date of SSc
disease manifestations - in particular, the date of onset
of scleroderma skin changes - was determined.
Statistical analyses
Univariate methods were used to compare independent
variables in patients with and without anti-RNAP. The t
test was used for continuous variables, and the chi-
square test and analysis of variance were used for cate-
gorical variables. Logistic and linear regression models
were used to identify and quantify independent corre-
lates of anti-RNAP, the highest recorded mRSS, and
malignancy diagnosed within 5 years of onset of SSc
skin disease. Collinearity between variables was taken
into consideration when selecting variables for inclusion
in the regression models.
Contingency table analysis was performed to deter-
mine the sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) - with corre-
sponding 95% confidence intervals (CIs) - of anti-RNAP
for prediction of various SSc disease manifestations in
our cohort.
In order to enable unbiased estimation of the associa-
tion between anti-RNAP and malignancy diagnosed
within 5 years of onset of SSc skin disease, we selected
patients for these particular analyses as follows: we
included all patients diagnosed with malignancy within
5 years - either before or after - of onset of SSc skin dis-
ease, together with all patients in whom a diagnosis of
malignancy had not been made but whose disease dura-
tion was at least 5 years at the time of analysis of data.
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attempt to impute these data. The number of patients
on whom each of the analyses were performed is listed
in the results tables.
All P values were two-tailed and statistical significance
was defined as P ≤ 0.05. All statistical analyses were per-
formed using SAS software version 9.1 (SAS Institute
Inc., Cary, NC, USA). Figure 1, a dot plot of the time
interval (years) between onset of SSc skin disease and
diagnosis of malignancy, according to malignancy type,
was generated using STATA software (StataCorp LP,
College Station, TX, USA).
Results
Patient characteristics
The characteristics of patients in the present study are
summarized in Table 1. Among 451 patients who were
included in the study, 397 (88.0%) were female, 319
(70.7%) had limited disease, and 132 (29.3%) had diffuse
disease. The majority of patients were Caucasian
(94.3%), with Asian and Aboriginal-Islander patients
comprising 3.9% and 1.8% of the participants,
respectively. The mean ± standard deviation (SD) ages
at disease onset and at recruitment were 46.5 ± 13.7
and 58.1 ± 12.4 years, respectively. The mean ± SD dis-
ease durations at recruitment and at the time of the
study were 11.6 ± 10.0 years and 13.6 ± 10.3 years,
respectively, in keeping with a group of patients with
predominantly prevalent disease. However, 84 (18.6%)
patients had been recruited within 2 years of diagnosis,
and 151 (33.5%) within 5 years of diagnosis of SSc.
From disease diagnosis to the time of the study, all
patients manifested Raynaud’s phenomenon, while 43%
developed digital ulcers, many of them multiple (25%
had six or more ulcers during the course of disease).
Digital gangrene or amputation occurred in 6.4% of
patients. Thirty-two (7.1%) patients had tendon friction
rubs and 166 (36.8%) patients had joint contractures.
Synovitis and myositis were disease features in 21.7%
and 0.9% of patients, respectively. Twenty-four (5.4%)
patients developed renal crisis; among these, six (25%)
patients required dialysis and two (8.3%) patients had
renal transplantation. Systemic hypertension affected
42.8% of patients. All patients had one or more type of
Figure 1 Time interval between systemic sclerosis onset and diagnosis of malignancy. Systemic sclerosis (SSc) onset was defined based
on onset of skin change. Symbols to the left of the vertical line (denoting time = 0 years) represent malignancies diagnosed prior to the onset
of SSc. Solid organ malignancies include breast, lung, colorectal, genitourinary and reproductive tract malignancies. Hematopoeitic malignancies
include lymphoma, leukemia and multiple myeloma. Nonmelanoma skin cancers include basal cell and squamous cell carcinomas. The ‘other’
category includes neoplastic variants and pre-neoplastic disorders. RNAP, anti-RNA polymerase III antibody.
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Characteristic Total
a n (%) or mean ± SD
Sex 451
Female 397 (88.0%)
Male 54 (12.0%)
Race 435
Caucasian 413 (94.3%)
Asian 17 (3.9%)
Aboriginal-Islander 8 (1.8%)
Age (years)
At disease onset
b 441 46.5 ± 13.7
At recruitment 448 58.1 ± 12.4
Disease duration (years)
At recruitment 441 11.6 ± 10.0
At time of the study
c 441 13.6 ± 10.3
Recruited within 2 years of SSc onset
b 451 84 (18.6%)
Recruited within 5 years of SSc onset
b 451 151 (33.5%)
Duration of follow-up
c,d (years) 315 1.9 ± 0.8
Disease subtype
e 451
Limited 319 (70.7%)
Diffuse 132 (29.3%)
Disease manifestations
f
Raynaud’s phenomenon 436 436 (100%)
Digital ulcers 451 194 (43.0%)
Tendon friction rub 451 32 (7.1%)
Joint contractures 451 166 (36.8%)
Highest mRSS during follow-up
g 434 11.7 ± 9.6
Synovitis 451 98 (21.7%)
Myositis 451 4 (0.9%)
Renal crisis
h 451 24 (5.4%)
Systemic hypertension
i 444 190 (42.8%)
Gastrointestinal involvement
j 451 451 (100%)
Pulmonary arterial hypertension
k 451 49 (10.9%)
Interstitial lung disease
l 451 139 (30.8%)
Cardiac involvement
m 451 31 (6.9%)
Serologic profile
n
Antinuclear antibodies 451 433 (96.0%)
Anti-centromere pattern 450 197 (43.8%)
Anti-RNA polymerase III antibody 451 69 (15.3%)
Anti-topoisomerase antibodies 446 79 (17.7%)
Anti-histidyl-tRNA synthetase antibodies 446 0 (0%)
Anti-ribonucleoprotein antibodies 445 4 (0.9%)
Anti-Ro antibodies 446 27 (6.1%)
Anti-La antibodies 446 6 (1.4%)
Anti-Smith antibodies 445 1 (0.2%)
Anti-double-stranded DNA antibodies 298 6 (2.0%)
Anti-polymyositis-scleroderma antibodies 447 4 (0.9%)
Anti-neutrophil cytoplasmic antibodies 437 73 (16.7%)
Myeloperoxidase specificity 436 12 (2.8%)
Proteinase-3 specificity 436 15 (3.4%)
Rheumatoid factor 423 126 (29.8%)
Anti-phospholipid antibodies 436 138 (31.7%)
Lupus anticoagulant 325 7 (2.2%)
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developing anal incontinence. PAH was diagnosed in 49
(10.9%) patients and ILD in 139 (30.8%) patients. Conse-
quently, nine patients required home oxygen therapy.
SSc cardiac involvement occurred in 31 (6.9%) patients.
During the mean ± SD follow-up of 1.9 ± 0.8 years, the
mean modified Rodnan skin score was 11.7 ± 9.6 points.
Overall, 42.0% of patients in the present study had ever
smoked.
The autoantibody profile of patients is summarized in
Table 1. Overall, 96% had antinuclear antibodies, with
43.8% having a centromere pattern and 17.7% having
anti-Scl70 (anti-topoisomerase) antibodies. Sixty-nine
(15.3%) patients had anti-RNAP. Other antibodies that
were found in a significant proportion of patients were
anti-Ro antibodies (6.1%), anti-neutrophil cytoplasmic
antibodies (16.7%), rheumatoid factor (29.8%) and anti-
phospholipid antibodies (31.7%).
A total of 198 (43.9%) patients had ever been treated
with corticosteroids, 74 (16.4%) patients with antimalar-
ials, 143 (31.7%) patients with immunosuppressives and
five (1.1%) patients with biological therapies.
Univariate comparisons
Univariate comparisons of characteristics of patients
with (anti-RNAP
+)a n dw i t h o u t( a n t i - R N A P
-)a n t i -
RNAP are summarized in Table 2. Patients with anti-
RNAP were more likely to have diffuse disease (75.4%
vs. 20.9%, P < 0.0001), joint contractures (73.9% vs.
30.1%, P < 0.0001), and greater highest-recorded mRSS
(20.6 ± 12.4 vs. 10.1 ± 7.9, P < 0.0001), indicating
more severe skin involvement. Patients with anti-
RNAP were also more likely to have synovitis (31.9%
vs. 19.9%, P = 0.03) and myositis (2.9% vs. 0.5%, P =
0.05). Renal crisis was significantly more prevalent
among those with anti-RNAP (24.6% vs. 1.8%, P <
0.0001). Among those who developed renal crisis, how-
ever, anti-RNAP was not associated with worse out-
come as determined by highest serum creatinine,
lowest estimated glomerular filtration rate, or the need
for dialysis and renal transplantation. Anti-RNAP was
also positively associated with systemic hypertension
(59.4% vs. 39.7%, P = 0.002) and negatively associated
with anti-centromere antibodies (5.8% vs. 50.7%, P <
0.0001), anti-Scl70 antibodies (1.5% vs. 20.7%, P =
0.0001), anti-phospholipid antibodies (13.9% vs. 34.8%,
P = 0.0008) and rheumatoid factor (12.5% vs. 32.9%, P
= 0.001), meaning that those with anti-RNAP were less
likely to have these other autoantibodies. Those with
anti-RNAP were more likely to have been treated with
corticosteroids (58.0% vs. 41.4%, P = 0.01) and immu-
nosuppressives (58.0% vs. 27.0%, P < 0.0001), in keep-
ing with more severe disease.
There were no other statistically significant differences
in demographic, disease and treatment related character-
istics among anti-RNAP
+ and anti-RNAP
- patients.
Table 1 Patient characteristics (n = 451) (Continued)
Treatment
f 451
Corticosteroids 198 (43.9%)
Antimalarials
o 74 (16.4%)
Immunosuppressives
p 143 (31.7%)
Biological therapies
q 5 (1.1%)
Smoking ever 436 183 (42.0%)
Malignancy
r 451 64 (14.2%)
Solid organ
s 35 (7.8%)
Hematopoietic
t 7 (1.6%)
Skin (nonmelanoma)
u 13 (2.9%)
Melanoma 6 (1.3%)
Other
v 3 (0.7%)
Time interval between SSc onset
w and malignancy diagnosis (years) 9.3 ± 8.1
mRSS, modified Rodnan skin score; n (%), number (percentage); SD, standard deviation; SSc, systemic sclerosis.
aTotal number of patients in whom data were
available for analysis.
bDisease onset defined as date of onset of first SSc-related manifestation other than Raynaud’s phenomenon.
cAs at 13 December 2010.
dMean duration of follow-up calculated for those who had more than one annual visit.
eDisease subtype classified based extent of skin involvement, with limited
disease being confined to extremities and face.
fEver from disease onset to most recent visit.
gScores range from 0 to 51, with higher scores indicating more
severe skin involvement.
hRenal crisis defined as abrupt onset severe hypertension (systolic blood pressure (BP) ≥ 180 mmHg and/or diastolic BP ≥ 100 mmHg)
without an alternate etiology, with or without rising creatinine or microangiopathic anemia.
iSystolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg.
jGastrointestinal involvement defined as one or more of reflux esophagitis, esophageal stricture or dysmotility, gastric antral vascular ectasia, bowel dysmotility or
pseudo-obstruction.
kPulmonary arterial hypertension defined as mean pulmonary arterial pressure ≥ 25 mmHg at rest with pulmonary capillary wedge pressure
≤ 15 mmHg.
lInterstitial lung disease defined by high-resolution computerized tomography scan of the lung.
mPresence of either left ventricular systolic or
diastolic dysfunction where no other cause was identified, or a conduction disturbance unexplained by other mechanisms, or a characteristic histological picture
on endomyocardial biopsy.
nAt recruitment.
oHydroxychloroquine.
pIncludes methotrexate, azathioprine, mycophenolate mofetil, cyclosporine and
cyclophosphamide.
qIncludes TNF antagonists and rituximab.
rEver from birth to most recent visit.
sIncludes breast, lung, colorectal, genitourinary and
reproductive tract malignancies.
tIncludes lymphoma, leukemia and multiple myeloma.
uIncludes basal cell and squamous cell carcinomas.
vIncludes neoplastic
variants and pre-neoplastic disorders.
wHere SSc onset defined based on onset of skin change.
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Anti-RNAP
+ (n = 69) Anti-RNAP
- (n = 382)
Characteristic Total
a n (%) or mean ± SD Total
a n (%) or mean ± SD P value
Sex 69 382
Female 58 (84.1%) 339 (88.7%) 0.27
Male 11 (15.9%) 42 (11.1%)
Race 65 373
Caucasian 61 (93.9%) 352 (94.4%) 0.97
Asian 3 (4.6%) 14 (3.8%)
Aboriginal-Islander 1 (1.5%) 7 (1.9%)
Age (years)
At disease onset
b 68 47.0 ± 11.7 373 46.4 ± 14.0 0.70
At recruitment 68 56.0 ± 12.1 380 58.4 ± 12.4 0.14
Disease duration (years)
At recruitment 68 9.0 ± 7.9 373 12.1 ± 10.3 0.02
At the time of the study
c 68 11.4 ± 8.1 373 14.1 ± 10.7 0.06
Duration of follow-up
c (years) 59 1.9 ± 0.9 256 1.9 ± 0.8 0.97
Disease subtype
d 69 382
Limited 17 (24.6%) 302 (79.1%) < 0.0001
Diffuse 52 (75.4%) 80 (20.9%)
Disease manifestations
e
Raynaud’s phenomenon 66 66 (100%) 370 370 (100%) 1.0
Digital ulcers 69 35 (50.7%) 382 159 (41.6%) 0.16
Tendon friction rubs 69 8 (11.6%) 382 24 (6.3%) 0.12
Joint contractures 69 51 (73.9%) 382 115 (30.1%) < 0.0001
Highest mRSS during follow-up
f 68 20.6 ± 12.4 366 10.1 ± 7.9 < 0.0001
Synovitis 69 22 (31.9%) 382 76 (19.9%) 0.03
Myositis 69 2 (2.9%) 382 2 (0.5%) 0.05
Renal crisis
g 69 17 (24.6%) 382 7 (1.8%) < 0.0001
Systemic hypertension
h 69 41 (59.4%) 375 149 (39.7%) 1.0
Gastrointestinal involvement
i 69 69 (100%) 382 379 (100%) 0.75
Pulmonary arterial hypertension
j 69 7 (10.1%) 382 42 (11.0%) 0.52
Interstitial lung disease
k 69 19 (27.5%) 382 120 (31.4%) 0.80
Cardiac involvement
l 69 7 (10.1%) 382 24 (6.3%) 0.24
Serologic profile
m 69
Antinuclear antibodies 67 (97.1%) 382 366 (95.8%) 0.61
Anti-centromere pattern 4 (5.8%) 381 193 (50.7%) < 0.0001
Anti-topoisomerase antibodies 1 (1.5%) 377 78 (20.7%) 0.0001
Anti-histidyl-tRNA synthetase antibodies 0 (0%) 377 0 (0%) 1.0
Anti-ribonucleoprotein antibodies 1 (1.5%) 376 3 (0.8%) 0.6
Anti-Ro antibodies 3 (4.4%) 377 24 (6.4%) 0.52
Anti-La antibodies 0 (0%) 377 6 (1.6%) 0.29
Anti-Smith antibodies 44 0 (0%) 376 1 (0.3%) 0.67
Anti-double stranded DNA antibodies 69 0 (0%) 254 6 (2.4%) 0.30
Anti-polymyositis-scleroderma antibodies 64 0 (0%) 378 4 (1.1%) 0.39
Anti-neutrophil cytoplasmic antibodies 64 10 (15.6%) 373 63 (16.9%) 0.80
Myeloperoxidase specificity 64 4 (16.3%) 372 8 (2.2%) 0.06
Proteinase-3 specificity 64 2 (13.1%) 372 13 (3.5%) 0.88
Rheumatoid factor 65 8 (12.5%) 359 118 (32.9%) 0.001
Anti-phospholipid antibodies 43 9 (13.9%) 371 129 (34.8%) 0.0008
Lupus anticoagulant 69 0 (0%) 282 7 (12.5%) 0.30
Treatment
e 69 382
Corticosteroids 40 (58.0%) 158 (41.4%) 0.01
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In logistic regression modeling, anti-RNAP were inde-
pendently associated with renal crisis (odds ratio (OR)
3.8, 95% CI 1.2 to 11.5, P = 0.02), diffuse disease sub-
type (OR 6.4, 95% CI 2.9 to 13.8, P < 0.0001) and joint
contractures (OR 2.5, 95% CI 1.2 to 5.3, P =0 . 0 2 )
(Table 3). In the same model, anti-RNAP was negatively
correlated with anti-Scl70 antibodies (OR 0.01, 95% CI
0.002 to 0.11, P < 0.0001) and anti-centromere antibo-
dies (OR 0.13, 95% CI 0.04 to 0.41, P = 0.0005). After
adjustment for these statistically significant covariates,
myositis and synovitis were no longer significantly asso-
ciated with anti-RNAP.
Results of linear regression analysis for independent
correlates of highest-recorded mRSS (log10 transformed
to follow a normal distribution) during follow-up are
presented in Table 4. Anti-Scl70 antibodies (parameter
estimate 4.37, standard error 0.98, P < 0.0001), anti-
RNAP (parameter estimate 7.67, standard error 1.09, P
< 0.0001) and joint contractures (parameter estimate
Table 3 Independent correlates of antibodies to RNA
polymerase III determined using logistic regression
Variable
a Odds
ratio
95% confidence
interval
P
value
Renal crisis
b 3.8 1.2 to 11.5 0.02
Diffuse subtype
c 6.4 2.9 to 13.8 <
0.0001
Joint contractures 2.5 1.2 to 5.3 0.02
Anti-topoisomerase
antibodies
0.01 0.002 to 0.11 <
0.0001
Anti-centromere
antibodies
0.13 0.04 to 0.41 0.0005
In this model, after adjustment for other significant covariates, myositis and
synovitis were no longer statistically significant and were therefore removed
from model. Univariate odds ratio of RNA polymerase III for renal crisis is 17.4
(95% confidence interval 6.9 to 43.9, P < 0.0001).
aEver from disease onset
(defined as date of onset of first systemic-sclerosis-related manifestation other
than Raynaud’s phenomenon) to most recent visit.
bRenal crisis defined as
abrupt onset severe hypertension (systolic blood pressure ≥ 180 mmHg and/
or diastolic blood pressure ≥ 100 mmHg) without an alternate etiology, with
or without microangiopathic anemia or decline in renal function.
cDisease
subtype classified based on extent of skin involvement, with limited disease
being confined to extremities and face.
Table 2 Univariate comparison of characteristics of patients with and without antibodies to RNA polymerase III
(Continued)
Antimalarials
n 10 (14.5%) 64 (16.8%) 0.64
Immunosuppressives
o 40 (58.0%) 103 (27.0%) < 0.0001
Biological therapies
p 1 (1.5%) 4 (1.1%) 0.77
Smoking ever 65 30 (46.2%) 371 153 (41.2%) 0.44
Malignancy
e 69 14 (13.0%) 382 50 (13.2%) 0.37
Solid organ
q 9 (13.0%) 26 (6.8%)
Hematopoietic
r 0 (0%) 7 (1.8%)
Skin (nonmelanoma)
s 4 (5.8%) 9 (2.4%)
Melanoma 1 (1.5%) 5 (1.3%)
Other
t 0 (0%) 3 (0.8%)
Malignancy diagnosed within 5 years of onset of SSc
u,v 45 6 (13.3%) 254 10 (3.9%) 0.01
Time interval between SSc onset and malignancy diagnosis (years)
u 9 4.1 ± 3.1 37 11.7 ± 9.1 0.0002
Malignancy in inception cohort
e,w 31 120 0.42
Solid organ
q 46
Hematopoietic
r 01
Skin (nonmelanoma)
s 13
Melanoma 0 0
Other
t 00
anti-RNAP, anti-RNA polymerase III antibodies; mRSS, modified Rodnan skin score; n (%), number (percentage); SD, standard deviation; SSc, systemic sclerosis.
aRefers to the total number of patients in whom data were available for analysis.
bDisease onset defined as date of onset of first SSc-related manifestation other
than Raynaud’s phenomenon.
cAs at 13 December 2010.
dDisease subtype classified based extent of skin involvement, with limited disease being confined to
extremities and face.
eEver from birth to most recent visit.
fScores range from 0 to 51, with higher scores indicating more severe skin involvement.
gRenal crisis
defined as abrupt-onset severe hypertension (systolic blood pressure (BP) ≥ 180 mmHg and/or diastolic BP ≥ 100 mmHg) without an alternate etiology, with or
without microangiopathic anemia or decline in renal function.
hDiastolic BP ≥ 90 mmHg or systolic BP ≥ 140 mmHg.
iGastrointestinal involvement defined as one
or more of reflux esophagitis, esophageal stricture or dysmotility, gastric antral vascular ectasia, bowel dysmotility or pseudo-obstruction.
jPulmonary arterial
hypertension defined as mean pulmonary arterial pressure ≥ 25 mmHg at rest with pulmonary capillary wedge pressure ≤ 15 mmHg.
kInterstitial lung disease
defined by high-resolution computerized tomography scan of the chest.
lPresence of either left ventricular systolic or diastolic dysfunction where no other cause
was identified, or a conduction disturbance unexplained by other mechanisms, or a characteristic histological picture on endomyocardial biopsy.
mAt recruitment.
nHydroxychloroquine.
oIncludes methotrexate, azathioprine, mycophenolate mofetil, cyclosporine and cyclophosphamide.
pIncludes TNF antagonists and
rituximab.
qIncludes breast, lung, colorectal, genitourinary and reproductive tract malignancies.
rIncludes lymphoma, leukemia and multiple myeloma.
sIncludes
basal cell and squamous cell carcinomas.
tIncludes neoplastic variants and pre-neoplastic disorders.
uExcluding nonmelanoma skin cancers and the ‘other’
category; here SSc onset defined based on onset of skin change.
vDenominator of 299 determined by adding the number of patients who had malignancy
diagnosed within 5 years of diagnosis of SSc and all other patients in whom a diagnosis of malignancy had not been made but whose disease duration was ≥ 5
years as of 13 December 2010 (date at which data were censored for analysis).
wPatients recruited within 5 years of onset of SSc skin changes.
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pendently associated with highest-recorded mRSS. As
the diffuse disease subtype and anti-Scl70 antibodies
were highly correlated (collinear), only the latter was
included in the model.
Further renal crisis analyses
In 10 of the 24 cases of renal crisis, the diagnosis was
based solely on new-onset severe hypertension (systolic
BP ≥ 180 mmHg and/or diastolic BP ≥ 100 mmHg)
without an alternate etiology. When analyses were lim-
ited to the 14 patients in whom the diagnosis was based
on new-onset severe hypertension and one or both of
microangiopathic anemia or decline in renal function,
nine patients had anti-RNAP (13.0% of total of 69 anti-
RNAP
+) while five patients did not have anti-RNAP
(1.31% of total of 382 anti-RNAP
-)( P < 0.0001). Further
logistic regression analysis, limited to those with renal
crisis based on the latter definition, revealed a univariate
OR of renal crisis of 6.8 (95% CI 1.9 to 24.8, P = 0.004)
in the presence of anti-RNAP.
Malignancy analyses
Among 451 patients in this study, 64 (14.2%) patients
had ever been diagnosed with malignancy, either pre-
dating or post-dating the onset of SSc. There were 35
(7.8%) patients with solid organ malignancies, seven
(1.6%) patients with hematopoietic malignancies, 13
(2.9%) patients with nonmelanoma skin cancers, six
(1.3%) patients with melanoma and three (0.7%) patients
with other neoplastic variants and pre-malignant condi-
tions. The mean ± SD time interval between onset of
SSc skin changes and diagnosis of malignancy was 9.3 ±
8.1 years.
As seen in Table 2, there was no significant difference
in the number or type of malignancies ever diagnosed in
patients with or without anti-RNAP. Similarly, in a sub-
group analysis of 151 patients recruited within 5 years
of SSc skin onset, there was no significant difference in
the number or type of malignancies in patients with or
without anti-RNAP (Table 2). In the group as a whole,
however, the time interval between SSc skin onset and
the diagnosis of malignancy was shorter among anti-
RNAP
+ patients (4.1 ± 3.1 vs. 11.7 ± 9.1 years, P =
0.0002), and a higher proportion of malignancies were
diagnosed within 5 years of onset of SSc skin changes in
the anti-RNAP
+ group (13.3% vs. 3.9%, P =0 . 0 1 ) .T h e
time interval between SSc skin onset and diagnosis of
malignancy in anti-RNAP
+ and anti-RNAP
- patients is
depicted as a dot plot in Figure 1.
The results of logistic regression analysis of corre-
lates of malignancy, diagnosed within 5 years of SSc
skin onset, are summarized in Table 5. These corre-
lates were anti-RNAP (OR 4.2, 95% CI 1.3 to 13.4, P =
0.01) and older age at SSc skin onset (OR 1.10, 95% CI
1.05 to 1.16, P = 0.0002). In this model, after adjust-
ment for anti-RNAP and age at SSc skin onset, there
was no statistically significant association between
smoking, immunosuppressive use, disease subtype, and
malignancy.
Test properties of anti-RNAP
Test properties of anti-RNAP for prediction of various
clinical manifestations of SSc are summarized in Table
6. The PPV and NPV were determined based on a pre-
valence of anti-RNAP in our cohort of 15.3%. The pre-
valence of each of the clinical manifestations is listed in
Table 1. Overall, anti-RNAP had low PPV for all of the
manifestations listed in Table 6, except for diffuse SSc
subtype and joint contractures where the PPV was
75.4% (95% CI 63.5 to 84.9%) and 73.9% (95% CI 61.9
to 83.8%), respectively. The NPV was high for renal cri-
sis (NPV 98.2%, 95% CI 96.3 to 99.3%), myositis (NPV
99.5%, 95% CI 98.1 to 99.9%) and malignancy within 5
years of onset of SSc skin changes (NPV 96.1%, 95% CI
92.9 to 98.1%).
Discussion
In this cross-sectional analysis of longitudinally acquired
data on a large number (n = 451) of patients with SSc,
Table 4 Independent correlates of highest modified
Rodnan skin score recorded during follow-up,
determined using linear regression
Variable
a Parameter
estimate
Standard
error
P
value
Anti-topoisomerase
antibodies
4.37 0.98 <
0.0001
Anti-RNA polymerase III
antibodies
7.67 1.09 <
0.0001
Joint contractures 8.47 0.81 <
0.0001
aEver from disease onset (defined as date of onset of first systemic-sclerosis-
related manifestation other than Raynaud’s phenomenon) to most recent visit.
Table 5 Correlates of malignancy diagnosed within 5
years of systemic sclerosis onset
a, determined using
logistic regression
b
Variable
c Odds
ratio
95% confidence
interval
P
value
Anti-RNA polymerase III
antibodies
4.2 1.3 to 13.4 0.01
Age of onset of systemic
sclerosis
1.10 1.05 to 1.16 0.0002
Smoker NS
Immunosuppressives NS
Diffuse subtype NS
NS, not significant.
aBefore or after the onset of systemic sclerosis skin
disease.
bExcluding nonmelanoma skin cancers and the ‘other’ category.
cEver
from disease onset to most recent visit.
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Page 9 of 13anti-RNAP were present in 15.3%. Anti-RNAP were
independently correlated with renal crisis and more
severe skin manifestations including diffuse extent of
skin involvement, higher skin thickness scores and joint
contractures.
The 15.3% prevalence of anti-RNAP in our Australian
study is comparable with English (12%) and Canadian
(19.4%) studies, possibly reflecting a common racial ori-
g i ni nt h em a j o r i t yo fC a u c a s i a np a t i e n t si nt h e s e
cohorts [8,10]. Although we had relatively few Asians
and Aboriginal-Islanders, the prevalence of anti-RNAP
among these patients was comparable with the group as
a whole (3/17 (17.6%) in Asians and 1/8 (12.5%) among
Aboriginal-Islanders).
The prevalence of anti-RNAP among Australian SSc
patients is markedly greater than French (4 to 9.4%) and
Japanese (6%) SSc patients [5-7,19]. While genetic and
epigenetic factors may account for these differences,
selection bias may be an alternate explanation. Patients
with a more severe disease phenotype are more likely to
be referred to specialized centers such as ours, thus
leading to an overestimation of the frequency of anti-
RNAP among SSc patients.
Differences in the prevalence of anti-RNAP in various
countries have important implications in terms of the
usefulness of such antibodies in clinical practice. While
sensitivity and specificity are properties that are inherent
t oat e s t ,t h eP P Va n dN P Va r ep r e v a l e n c ed e p e n d e n t .
Furthermore, the frequency of each of the related clini-
cal manifestations of SSc - for example, renal crisis -
may differ among cohorts, again impacting PPV and
NPV calculations.
Overall, in our cohort, we have shown that one in four
patients with anti-RNAP develops renal crisis, while in
absence of this antibody only one in 50 patients devel-
ops this complication. The 25% PPV of developing renal
crisis with anti-RNAP in our cohort is comparable with
that reported in French and US cohorts, wherein the
PPV of renal crisis in the presence of anti-RNAP was
20% and 25%, respectively [7]. These findings make a
case for home BP monitoring and regular renal function
tests in patients with anti-RNAP. The role of prophylac-
tic treatment with angiotensin-converting enzyme inhi-
bitors in these patients is yet to be determined. It is
worth noting that a significantly higher proportion of
anti-RNAP
+ patients had ever been treated with corti-
costeroids than anti-RNAP
- patients (58.0% vs. 41.4%, P
= 0.01). This is likely to reflect the greater severity of
disease in the anti-RNAP
+ patients, and the association
of these antibodies with synovitis. Corticosteroid use has
previously been implicated as a risk factor for the devel-
opment of SSc renal crisis [20]. In logistic regression
modeling in our study, however, anti-RNAP were signif-
icantly associated with renal crisis, independently of cor-
ticosteroid use, which itself was not associated with
renal crisis.
In the present study, we have confirmed that anti-
RNAP is a marker for more severe SSc skin disease,
with three in four patients positive for the antibody
developing joint contractures. As the natural history of
skin thickening (scleroderma) in a proportion of patients
with SSc is progression early on, and regression after a
variable period [21], in this prevalent cohort we may
have missed the true peak of the mRSS. Nonetheless, we
h a v es h o w na na s s o c i a t i o nb e t w e e na n t i - R N A Pa n d
highest-recorded mRSS, independent of anti-Scl70 anti-
bodies. Prospective studies with long-term follow-up of
patients recruited from disease onset are required in
order to evaluate temporal variations in skin disease, in
terms of rate and extent of progression and regression,
among those with and without anti-RNAP.
Anti-RNAP are almost mutually exclusive of other
autoantibodies. We have here confirmed that anti-
RNAP are negatively correlated with anti-centromere
and anti-Scl70 antibodies and have also shown that this
phenomenon applies to other autoantibodies seen in
Table 6 Test properties of anti-RNAP for the prediction of various clinical manifestations in systemic sclerosis
Clinical manifestation
a Sensitivity (95% CI) Specificity (95% CI) Positive predictive value
(95% CI)
Negative predictive value
(95% CI)
Diffuse subtype 14.7% (11.2 to 18.8%) 82.5% (73.4 to 89.5%) 75.4% (63.5 to 84.9%) 20.9% (17.0 to 25.4%)
Joint contracture 30.7% (23.8 to 38.3%) 93.7% (90.2 to 96.2%) 73.9% (61.9 to 83.8%) 69.9% (65.0 to 74.5%)
Synovitis 22.5% (14.6 to 32.0%) 86.7% (82.7 to 90.1% 31.9% (21.2 to 44.2%) 80.1% (75.7 to 84.0%)
Myositis
b 50.0% (6.8 to 93.2%) 85.0% (81.4 to 88.2%) 2.9% (0.4 to 10.1%) 99.5% (98.1 to 99.9%)
Systemic hypertension 21.6% (16.0 to 28.1%) 89% (84.5 92.6%) 59.4% (46.9 to 71.1%) 60.3% (55.1 to 65.3%)
Renal crisis 70.8% (48.9 to 87.4%) 87.8% (84.3 to 90.8%) 24.6% (15.1 to 36.5%) 98.2% (96.3 to 99.3%)
Malignancy
b (all types) 21.9% (12.5 to 34.0%) 85.8% (81.9 to 89.1%) 20.3% (11.6 to 31.7%) 86.9% (83.1 to 90.1%)
Malignancy
b,c (certain types) 20.8% (10.5 to 35.0%) 85.8% (81.9 to 89.1%) 15.4% (7.6 to 2.6%) 89.7% (86.2 to 92.6%)
Malignancy within 5 years of SSc
onset
c
37.5% (15.2 to 64.6%) 86.2% (81.7 to 90.0%) 13.3% (5.1 to 16.8%) 96.1% (92.9 to 98.1%)
anti-RNAP, anti-RNA polymerase III antibodies; CI, confidence interval; SSc, systemic sclerosis.
aEver from disease onset to most recent visit; except for malignancy,
which was ever from birth to most recent visit.
bChi-square P > 0.05 in univariate analysis.
cExcluding nonmelanoma skin cancers and the ‘other’ category.
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plasmic antibodies, rheumatoid factor and anti-phospho-
lipid antibodies. These findings point also to a quasi
segregation of associated disease manifestations. For
example, among patients in our study only one patient
had all of renal crisis, PAH and ILD, while only two
patients had both renal crisis and PAH, and only four
patients had both renal crisis and ILD.
To date, the association between anti-RNAP and mus-
culoskeletal manifestations of SSc has not been fully
characterized. While small numbers of patients limited
our ability to demonstrate independent associations in
this regard, we did find univariate associations between
anti-RNAP and each of synovitis and myositis. While
the PPV of anti-RNAP for these manifestations was low,
NPVs were high: 80.1% (95% CI 75.7 to 84.0%) for syno-
vitis and 99.5% (95% CI 98.1 to 99.9%) for myositis. This
means that the occurrence of SSc myositis is highly
unlikely in the absence of anti-RNAP. One should, how-
ever, note that myositis and scleroderma are among the
characteristic features of mixed connective tissue dis-
ease, and patients with mixed connective tissue disease
were not included in the present study.
T h ep r e s e n ts t u d yh a ss e v e r a l limitations. Although
one-third of the patients in our study were recruited
within 5 years of disease onset, the majority had preva-
lent disease of more than 5 years’ duration at enrolment.
As anti-RNAP are associated with a more severe disease
phenotype, our findings may be affected by survival bias
- wherein those with anti-RNAP-related complications
such as renal crisis may have succumbed prior to enrol-
ment, leading to an underestimation of the prevalence
of the antibody and the severity of its associations.
Another limitation of the study is its cross-sectional
design. Although disease manifestations and treatment
were defined as present ever from disease onset to the
time of analysis, the retrospective nature of some of the
data increases the possibility of misclassification. While
we used prospectively collected data for many variables
such as the mRSS, the prevalent nature of our cohort
and the relatively short period of follow-up are metho-
dological limitations.
In analyses of the relationship between anti-RNAP and
malignancy, we used the exact date of tissue diagnosis of
cancer, relative to the date of onset of SSc. Here, the
date of onset of SSc was defined as the date of onset of
skin changes, as several SSc patients with malignancy
had gastroesophageal reflux recorded as their first non-
Raynaud’s manifestation and we could not be certain
that this nonspecific symptom was truly related to SSc.
Notwithstanding the aforementioned limitations, we
have here shown a fourfold increased risk of malignancy
within 5 years pre-dating or post-dating the onset of
SSc skin disease, among those who are positive for anti-
RNAP. This association is independent of disease sub-
type and age of onset of SSc. After adjustment for other
significant covariates, we were unable to demonstrate an
association between malignancy and treatment with
immunosuppressives among our patients. This may have
been due to sample size limitations, and further large-
scale prospective studies are needed to evaluate these
associations.
Sensitivity/specificity analysis revealed that almost 13%
of patients who have anti-RNAP develop cancer within
5 years of SSc skin onset. At present, however, there is
no evidence that screening for malignancy in newly
diagnosed SSc patients with anti-RNAP leads to
improved survival, and a PPV of only 13% would mean
many worried-well patients. The NPV of anti-RNAP for
the diagnosis of malignancy within 5 years of SSc onset
is high (NPV 96.1%, 95% CI 92.9 to 98.1%), offering
some reassurance.
The malignancies seen among our anti-RNAP
+
patients were predominantly solid organ cancers, with
one case of melanoma and fours cases of nonmelanoma
skin cancers. We did not document any hematopoietic
malignancies among the anti-RNAP
+ patients. Overall,
the most common cancer among the SSc patients in our
study was breast cancer, followed by melanoma, colorec-
tal cancer, lymphoma and lung cancer. It must be noted
that the majority of patients in our study were women
and that Australia as a whole has one of the highest pre-
valences of melanoma worldwide [22].
When we defined malignancy as present ever we did
not show an increased overall risk of cancer in those
with anti-RNAP, compared with those without. Given
the observed frequencies of cancer in anti-RNAP
+ and
anti-RNAP
- patients, our study was powered to show a
sixfold increased risk of malignancy in patients with
anti-RNAP (a = 0.05, b =0 . 2 ) .T h es t u d yw a st h e r e f o r e
underpowered to demonstrate a weaker but still signifi-
cant association. There are several other possible expla-
nations. As patients had prevalent disease at
recruitment, there may again have been a survival bias.
Also, in the process of carcinogenesis, many protective
and injurious factors are accrued over time and this
may alter the longer-term association between malig-
nancy and anti-RNAP in SSc. Alternatively, it is possible
that many SSc patients with anti-RNAP die younger as
a result of disease-related complications, before they
develop cancer.
Conclusions
The protean clinical correlates of anti-RNAP in our
cohort, wherein the prevalence of such antibodies is
15%, makes anti-RNAP one of the most useful antibo-
dies currently available for prognostication in SSc.
Important associations of anti-RNAP include increased
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Page 11 of 13risk of renal crisis, systemic hypertension, synovitis,
myositis, joint contractures and malignancy within a 5-
year timeframe before or after the onset of SSc skin dis-
ease. Where possible, these antibodies should be tested
in all SSc patients at baseline to guide monitoring and
follow-up.
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